BRAF (Ab-753) Antibody

What is BRAF (Ab-753) Antibody and what epitope does it recognize?

BRAF (Ab-753) Antibody is a rabbit polyclonal antibody specifically designed to recognize the Ab-753 region of the BRAF protein. It is used primarily for detection of B-Raf proto-oncogene serine/threonine-protein kinase in research applications . The antibody targets an epitope in the C-terminal region of BRAF, which is preserved in most BRAF variants, making it useful for detecting both wild-type BRAF and mutant forms in experimental settings. Unlike antibodies targeting the N-terminal domain, this antibody can detect fusion proteins where the N-terminal regulatory domain is deleted, as seen in several oncogenic BRAF fusions.

What are the fundamental signaling pathways involving BRAF that can be studied using this antibody?

BRAF (Ab-753) Antibody enables investigation of the RAF-MEK-ERK signaling pathway, a critical cascade in cell proliferation and differentiation. BRAF functions as a serine/threonine kinase in the RAS-RAF-MEK-ERK pathway, transmitting signals from membrane receptors to regulate gene expression . Specifically, researchers can use this antibody to:

• Analyze BRAF activation status in response to growth factors

• Investigate downstream ERK signaling effects

• Study feedback mechanisms within the MAPK pathway

• Examine cross-talk between MAPK and PI3K/AKT pathways

Understanding these pathways is essential as they represent major therapeutic targets in cancer treatment, particularly in tumors with BRAF alterations .

What are the optimal protocols for using BRAF (Ab-753) Antibody in Western blotting?

For optimal Western blotting results with BRAF (Ab-753) Antibody, researchers should follow this methodological approach:

Sample Preparation:

• Extract proteins using RIPA buffer supplemented with phosphatase inhibitors (essential when studying phosphorylation status)

• Load 25-50μg of total protein per lane

• Include positive controls (cell lines known to express BRAF, such as A375 melanoma cells)

Blotting Parameters:

• Transfer proteins to PVDF membrane (preferred over nitrocellulose for BRAF detection)

• Block with 5% BSA in TBST (not milk, which can interfere with phospho-epitope detection)

• Incubate with primary antibody at 1:1000 dilution overnight at 4°C

• Use HRP-conjugated anti-rabbit secondary antibody at 1:5000 dilution

Detection Considerations:

• BRAF appears at approximately 94 kDa

• Enhanced chemiluminescence detection systems provide optimal sensitivity

• For BRAF fusion proteins, expect altered molecular weights compared to wild-type BRAF

This protocol allows for reliable detection of BRAF protein levels across various experimental conditions while minimizing background and non-specific binding.

How can BRAF (Ab-753) Antibody be optimized for immunohistochemistry in FFPE tissue sections?

Optimizing BRAF (Ab-753) Antibody for immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded (FFPE) tissues requires careful attention to several methodological details:

Antigen Retrieval:

• Heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes is generally most effective

• Pressure cooker methods may provide superior results compared to water bath techniques

Antibody Parameters:

• Titrate antibody concentration between 1:100-1:400 dilution

• Incubate overnight at 4°C in humid chamber

• Use polymer-based detection systems rather than avidin-biotin methods for cleaner results

Controls and Validation:

• Include positive control tissues known to express BRAF (melanoma samples with known BRAF status)

• Include negative controls (omitting primary antibody and using non-BRAF expressing tissues)

• Validate staining pattern against mRNA expression data when possible

When optimizing for FFPE tissues specifically, these considerations are particularly important as formalin fixation can mask epitopes and create challenges for antibody binding . The protocol must be adjusted based on fixation time and storage conditions of archival tissues.

What methodological approaches should be used when combining BRAF (Ab-753) Antibody with specific BRAF mutation detection?

When researchers need to combine general BRAF detection with specific mutation identification, a multi-method approach is recommended:

Sequential Analysis Strategy:

• Initial screening with BRAF (Ab-753) Antibody to confirm BRAF expression

• Follow-up with mutation-specific antibodies (e.g., BRAF V600E-specific antibody)

• Confirmation with molecular techniques (PCR, sequencing) for definitive mutation identification

Complementary Techniques Table:

This integrated approach allows researchers to first confirm BRAF expression using the Ab-753 antibody before proceeding to more specific analyses of mutation status . The combination is particularly valuable when working with limited tissue samples or when screening large cohorts before more expensive molecular testing.

How can BRAF (Ab-753) Antibody be used to investigate different classes of BRAF mutations?

BRAF mutations can be classified into three distinct classes based on biochemical and signaling mechanisms. Using BRAF (Ab-753) Antibody in conjunction with other experimental techniques allows researchers to investigate these different classes:

Class 1 Mutations (V600E and other V600 variants):

• Use BRAF (Ab-753) Antibody in co-immunoprecipitation studies to examine monomeric signaling

• Combine with phospho-ERK antibodies to measure high kinase activity characteristic of Class 1 mutants

• Apply in RAS-independence assays to confirm pathway activation without RAS signaling

Class 2 Mutations (Non-V600 activating mutations, e.g., L485F, L525R):

• Employ BRAF (Ab-753) Antibody in dimerization studies (e.g., protein crosslinking followed by immunoblotting)

• Utilize in RAS-knockout cell models to confirm RAS-independent signaling

• Combine with dimerization-deficient mutants (R509H) to analyze signaling dependencies

Class 3 Mutations (Low kinase activity, e.g., F247L, R558Q):

• Apply BRAF (Ab-753) Antibody in CRAF co-immunoprecipitation experiments to detect BRAF-CRAF interactions

• Use in RAS-binding assays to demonstrate enhanced RAS dependency

• Combine with RAS-GTP pull-down assays to measure RAS activation levels

This classification approach provides crucial insights into the mechanistic differences between BRAF mutants, which has direct implications for therapeutic targeting and resistance mechanisms in cancer research.

What are the methodological considerations for using BRAF (Ab-753) Antibody in studying BRAF fusion proteins?

BRAF fusion proteins present unique challenges for detection and characterization. When using BRAF (Ab-753) Antibody to study these fusions, researchers should consider:

Detection Strategy:

• Western blotting will show altered molecular weights compared to wild-type BRAF (94 kDa)

• KIAA1549-BRAF fusions typically appear at 120-140 kDa depending on the fusion variant

• FAM131B-BRAF and other rare fusions will have distinct molecular weights based on fusion partner size

Validation Approach:

• Complement antibody detection with molecular techniques (RT-PCR, FISH)

• Use FISH with probes flanking the BRAF gene to detect chromosomal rearrangements

• Apply real-time PCR with primers designed to detect specific fusion breakpoints (e.g., KIAA1549-BRAF exon 16-9 variant)

Functional Analysis:

• Use the antibody in kinase activity assays to measure constitutive activation

• Apply in cellular localization studies to determine subcellular distribution of fusion proteins

• Combine with inhibitor studies to assess fusion-specific drug responses

This multi-faceted approach is necessary because BRAF fusions lack the N-terminal regulatory domain while maintaining the C-terminal kinase domain, resulting in constitutive activation through mechanisms distinct from point mutations .

How can BRAF (Ab-753) Antibody be integrated into multi-omics approaches for comprehensive BRAF pathway analysis?

Integrating BRAF (Ab-753) Antibody into multi-omics research requires strategic implementation across multiple platforms:

Proteomics Integration:

• Use in immunoprecipitation followed by mass spectrometry to identify BRAF interactome

• Apply in reverse-phase protein arrays for high-throughput analysis of BRAF pathway activation

• Combine with phospho-specific antibodies to map phosphorylation cascades downstream of BRAF

Transcriptomics Correlation:

• Correlate BRAF protein levels with RNA-seq data to identify transcriptional consequences

• Analyze BRAF-dependent gene expression signatures before and after pathway inhibition

• Identify target genes specifically associated with different BRAF mutation classes

Functional Genomics:

• Use in CRISPR-Cas9 screening validation to confirm phenotypic effects of BRAF pathway alterations

• Apply in synthetic lethality screens to identify context-dependent vulnerabilities

• Integrate with drug screening data to develop biomarker-driven therapeutic strategies

This integrated approach allows researchers to connect BRAF protein expression and activation with downstream molecular consequences, providing a systems-level understanding of BRAF signaling in both normal and pathological contexts .

What are the common sources of false positives/negatives when using BRAF (Ab-753) Antibody and how can they be mitigated?

When working with BRAF (Ab-753) Antibody, researchers may encounter several technical challenges that can lead to misleading results:

False Positive Sources and Solutions:

False Negative Sources and Solutions:

Quality Control Measures:

• Always include positive control samples with known BRAF expression

• Validate antibody batch performance before conducting critical experiments

• Consider using multiple antibodies targeting different BRAF epitopes for confirmation

• When possible, validate protein expression results with mRNA data

These rigorous quality control measures ensure reliable and reproducible results when working with BRAF (Ab-753) Antibody across different experimental systems and applications.

What methodological approaches should be used to validate BRAF (Ab-753) Antibody specificity in different experimental systems?

Validating antibody specificity is crucial for obtaining reliable research results. For BRAF (Ab-753) Antibody, comprehensive validation should include:

Genetic Validation Methods:

• CRISPR/Cas9 BRAF knockout controls to confirm absence of signal

• siRNA/shRNA knockdown to demonstrate reduced signal intensity proportional to knockdown efficiency

• Overexpression systems with tagged BRAF to confirm co-localization of signals

Biochemical Validation Approaches:

• Peptide competition assays using the immunizing peptide

• Western blotting with recombinant BRAF protein standards

• Mass spectrometry confirmation of immunoprecipitated proteins

Cross-Platform Validation:

• Correlation of IHC results with Western blotting quantification

• Comparison of protein detection with mRNA expression data

• Functional validation through kinase activity assays

This multi-faceted validation approach ensures that signals obtained using the BRAF (Ab-753) Antibody genuinely represent BRAF protein and not experimental artifacts or cross-reactivity with other proteins . Particularly important is the validation across different cell types and tissue contexts relevant to the specific research question.

How should researchers interpret varied BRAF expression patterns across different tumor types?

BRAF expression patterns vary significantly across tumor types and can yield important biological insights when properly interpreted:

Tissue-Specific Interpretation Guidelines:

Interpretation Framework:

• Compare expression levels with known mutation status

• Correlate with downstream pathway activation markers (phospho-ERK, phospho-MEK)

• Consider tumor heterogeneity and clonal evolution when expression is variable

• Integrate with patient-specific factors (tumor location, histological features)

What methodological considerations are important when using BRAF (Ab-753) Antibody to assess response to BRAF-targeted therapies?

When monitoring therapeutic responses with BRAF (Ab-753) Antibody, researchers should implement these methodological considerations:

Pre-Treatment vs. Post-Treatment Analysis:

• Establish baseline BRAF expression in pre-treatment samples

• Use consistent protocols for sample collection and processing

• Apply paired statistical analyses for matched pre/post samples

• Consider temporal dynamics (early vs. late responses)

Resistance Mechanism Investigation:

• Combine BRAF detection with analysis of bypass pathway activation (e.g., EGFR upregulation)

• Monitor for emergence of splice variants that may escape detection

• Assess for secondary mutations that may affect antibody binding

• Compare with functional readouts of pathway activity (phospho-ERK levels)

Clinical Trial Application Protocol:

This methodological approach is particularly important in the context of BRAF inhibitor resistance, where various adaptive mechanisms (EGFR upregulation, RAF dimerization, PI3K pathway activation) can emerge and affect treatment efficacy .

How can researchers integrate BRAF (Ab-753) Antibody data with BRAF mutation classification for precision oncology applications?

Integrating antibody-based BRAF detection with mutation classification creates a powerful approach for precision oncology:

Integrated Analysis Framework:

• First layer: BRAF protein expression (using BRAF Ab-753 Antibody)

• Second layer: BRAF mutation class determination (1, 2, or 3)

• Third layer: Pathway activation status (phospho-ERK, phospho-MEK levels)

• Fourth layer: Clinical and pathological correlates

Mutation Class-Specific Therapeutic Implications:

Precision Medicine Implementation:

• Use antibody data to stratify patients within mutation classes

• Develop therapy selection algorithms incorporating protein expression

• Monitor on-treatment biopsies for adaptive changes

• Identify novel biomarkers of response/resistance

This integrated approach recognizes that even within the same mutation class, variations in protein expression and pathway activation can influence therapeutic outcomes, enabling more nuanced treatment decisions in clinical settings .

What emerging methodologies might enhance the utility of BRAF (Ab-753) Antibody in single-cell analysis applications?

Single-cell technologies represent the frontier of cancer research, and several emerging methodologies can enhance BRAF (Ab-753) Antibody applications:

Single-Cell Protein Analysis Approaches:

• Mass cytometry (CyTOF) with metal-conjugated BRAF antibodies for multi-parameter analysis

• Imaging mass cytometry for spatial relationship analysis at single-cell resolution

• Microfluidic antibody-based proteomics for quantitative single-cell BRAF pathway analysis

• Digital spatial profiling combining BRAF antibody with spatial transcriptomics

Methodological Adaptations Required:

• Optimization of antibody conjugation chemistry to maintain epitope recognition

• Development of compatible fixation protocols preserving antigenicity

• Validation in cell line models with known BRAF status

• Correlation with genomic single-cell data for integrated analysis

These advanced methodologies will enable researchers to address critical questions about tumor heterogeneity, rare cell populations with specific BRAF alterations, and cellular consequences of differential BRAF signaling that are not possible with bulk tissue analysis .

How might BRAF (Ab-753) Antibody contribute to understanding the recently described molecular subtypes of BRAF-mutant cancers?

Recent research has identified distinct molecular subtypes within BRAF-mutant cancers that have important biological and clinical implications. BRAF (Ab-753) Antibody can contribute to this emerging field through:

Subtype Characterization Methodology:

• Quantitative assessment of BRAF protein levels across BM1/BM2 subtypes in colorectal cancer

• Co-staining with markers of each subtype (mTOR pathway, cell cycle regulators)

• Correlation of BRAF expression with epithelial-mesenchymal transition features in BM1

• Analysis of CDK1 and cyclin D1 co-expression in BM2 subtype

Subtype-Specific Functional Studies:

• Immunoprecipitation of BRAF complexes to identify subtype-specific interaction partners

• Analysis of differential response to BRAF/MEK inhibitors between subtypes

• Investigation of altered BRAF localization patterns in different subtypes

• Correlation with patient outcomes and treatment responses

This research direction has significant therapeutic implications, as understanding the molecular basis of these subtypes could lead to more personalized treatment approaches for BRAF-mutant cancers, moving beyond mutation status alone to incorporate broader pathway dependencies .